Molecular targeted agents in non-small-cell lung cancer

Clinical Lung Cancer

Volumn 5, Issue SUPPL. 1, 2003, Pages

  Sandler, Alan B ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Epidermal growth factor receptor tyrosine kinase; Gefitinib; Targeted therapies

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IRINOTECAN; ISIS 3521; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLACEBO; PRINOMASTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SULINDAC SULFONE; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL ACTIVITY; CELL GROWTH; CELL INVASION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; METASTASIS; MOLECULAR MECHANICS; MONOTHERAPY; NAUSEA AND VOMITING; NEUTROPENIA; SIGNAL TRANSDUCTION; SKIN DISEASE; TECHNOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0142124306     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2003.s.012     Document Type: Article

References (45)

1. American Cancer Society. Cancer Facts & Figures 200.3. Atlanta, GA. American Cancer Society, Inc. 2003:1-48.
2. Earle CC, Evans WK. Management issues for stage IV non-small cell lung cancer. Cancer Control 1997; 4:307-316.
3. Sandler A, Ettinger DS. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 1999; 4:241-251.
4. Novello S, Galli L, Antonuzzo A, et al. Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer. Lung Cancer 2001; 34:261-269.
5. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13:1860-1870.
6. Gatzemeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. EurJ Cancer 1996; 32A:243-248.
7. Scagliotti GV, De Marinis F, Rinaldi M, et al, on behalf of the Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 2001; 20:308a (Abstract #1228).
8. Van Meerbeeck JP, Smit EF, Lianes P, et al, for the EORTC-Lung Cancer Group. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small-cell clung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:308a (Abstract #1228).
9. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
10. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-3218.
11. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18:623-631.
12. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-641.
13. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18:122-130.
14. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16:2459-2465.
15. Schiller JH, Harrington D, Sandler A, et al. E1594: a randomized phase III ECOG trial in advanced nonsmall cell lung cancer. Plenary session presented at: American Society of Clinical Oncology; May 22, 2000; Washington, D.C.
16. Herbst RS, Hidalgo M, Pierson AS, et al. Angiogenesis inhibitors in clinical development for lung cancer. Semin Oncol 2002; 29:66-77.
17. Schmidt M, Maurer-Gebhard M, Groner B, et al. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors. Oncogene 1999; 18:1711-1721.
18. Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 2000; 59:753-767.
19. Yuen A, Halsey J, Ficher G, et al. Phase I/II trial of ISIS3521, an antisense inhibitor of PKC-α, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol 2001; 20:309a (Abstract #1234).
20. Isis Pharmaceuticals and Eli Lilly and Company announce results of Affinitak™ phase III clinical trial in non-small cell lung cancer [press release]. Carlsbad, CA and Indianapolis, IL: Isis Pharmaceuticals, Inc.; Eli Lilly and Company; March 17, 2003.
21. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999; 17:259-269.
22. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53:2379-2385.
23. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3:515-522.
24. Fontanini G, Vignati S, Bigini D, et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 1995; 31A:178-183.
25. Seth D, Shaw K, Jazayeri J, et al. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells. Br J Cancer 1999; 80:657-669.
26. Chernoff J. Protein tyrosine phosphatases as negative regulators of mitogenic signaling. J Cell Physiol 1999; 180:173-181.
27. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 1992; 89:2965-2969.
28. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:310a (Abstract #1235).
29. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-3279.
30. Kris MG, Herbst R, Rischin D, et al. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839 (Iressa TM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer 2000; 29(suppl 1):72 (Abstract #233).
31. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
32. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002; 21:292a (Abstract #1166).
33. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12:199-220.
34. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractor colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20:3a (Abstract #7).
35. Hong WK, Arquette M, Nabell L, et al. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2001; 20:224a (Abstract #895).
36. Abbruzzese JL, Rosenberg A, Xiong Q, et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2001; 20:130a (Abstract #518).
37. Raben D, Helfrich B, Chan Dea. C225 anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung caner (NSCLC) cells in vitro and in vivo. Proc Am Soc Clin Oncol 2001; 20:257a (Abstract #1026).
38. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77:527-543.
39. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19:843-850.
40. DeVore RF, Fehrenbacher L, Herbst RS, et al. A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 2000; 19:485a (Abstract #1896).
41. Masferrer J. Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J 2001; 7(suppl 3):S144-S150.
42. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946-1952.
43. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 2002; 29:78-86.
44. Smylie M, Mercier R, Aboulafia D, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:307a (Astract #1226).
45. Mininberg ED, Herbst RS, Henderson T, et al. Phase I/II study of the recombinant humanized monoclonal anti-VEGF antibody bevacizumab and the EGFR-TK inhibitor erlotinib in patients with recurrent non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003; 22:627 (Astract #2521).